Nemysis
Private Company
Funding information not available
Overview
Nemysis is a private, pre-revenue biotech founded in 2016, developing microbiome-friendly nutritional therapeutics. Its lead programs include IHAT, a novel nano-particulate iron supplement designed to mimic natural absorption, and E40, an endoprotease for degrading immunogenic gluten peptides. The company has attracted strategic investments from European pharmaceutical firms and is advancing its pipeline through academic collaborations, targeting significant unmet needs in iron deficiency and celiac disease management.
Technology Platform
Platform focused on developing microbiome-friendly nutritional therapeutics using bioinspired nanotechnology (e.g., IHAT nano-particulate iron) and a proprietary gastro-protective delivery matrix for targeted release in the small intestine.
Opportunities
Risk Factors
Competitive Landscape
Nemysis competes in the large iron supplement market against dominant OTC brands and generic pharmaceuticals, differentiating on tolerability. In celiac disease, it faces potential competition from other biotechs developing gluten-degrading enzymes (e.g., latiglutenase, TAK-062). Its key competitive advantage is the integrated focus on microbiome preservation across its portfolio.